Table 1.

Comparison of baseline data between intravitreal aflibercept and bevacizumab for macular edema secondary to branch retinal occlusion.

	Aflibercept (n = 50)	Bevacizumab (n = 54)	p value
Age (years)	63.3 ± 6.9	62.7 ± 5.5	0.34
Gender (male : female)	13 : 12	12 : 15	0.12
Lens status (phakic : pseudophakic)	22 : 3	20 : 7	0.09
Diabetic patients	10	16	0.19
Duration of symptoms (days)	22.1 ± 6.2	25.8 ± 7.4	0.23
Central foveal thickness (μm)	470.2 ± 99.3	459.4 ± 96.5	0.15
Best-corrected visual acuity (logMAR)	0.77 ± 0.43	0.72 ± 0.51	0.17